Visby Medical, a leader in rapid, at-home polymerase chain reaction (PCR) diagnostics, announced it has raised approximately $55 million, with the potential to reach $65 million, in its latest financing round led by Catalio Capital Management. The funding round also saw participation from existing investors, including ND Capital, Cedars Sinai Medical Center, Blue Water Life Science Advisors, Pitango Ventures, and John Doerr. These funds will advance the launch and distribution of Visby Medical’s recently FDA-authorized at-home Women’s Sexual Health Test, further solidifying the company’s strategic focus as the premier provider of at-home testing solutions.
New board member: In connection with the funding round, Catalio Partner Isaac Ro joins Visby Medical’s board as an observer. And Chuck Alpuche, Chief Operating Officer at Imperative Care, former EVP and Chief Operating Officer at Insulet Corporation, and senior executive at PepsiCo, joins Visby Medical’s board as an independent director.
Visby Medical’s at-home Women’s Sexual Health Test is the first single-use and disposable PCR diagnostic that delivers results within 30 minutes through a connected smartphone app. Upon receiving positive results, users are seamlessly connected with telemedicine providers for consultation and treatment, enhancing healthcare accessibility and privacy. The product will be available starting in July 2025 through direct-to-consumer channels.
KEY QUOTES:
“We are excited to partner with Catalio Capital Management, a true industry powerhouse, as we advance our mission to transform healthcare through rapid and convenient at-home diagnostics that deliver the same accuracy as traditional PCR machines. This funding round will enable Visby to deliver on our vision of empowering consumers with reliable and lab-accurate health information from the comfort of their homes, starting with our at-home test for sexually transmitted infections for women.”
Adam de la Zerda, PhD, Founder and CEO of Visby Medical
“Visby Medical has delivered the first and only laboratory-grade STI testing solution that can be made directly accessible to individuals. We were eager to invest in Visby ahead of their FDA clearance, knowing this would represent a breakthrough moment for the diagnostics industry. We are proud to support the company in its mission to reshape healthcare delivery.”
Isaac Ro
“I am thrilled to join Visby Medical’s board at this transformative time. Visby’s FDA-authorized at-home STI test is redefining convenience and accessibility in diagnostics, and now the company is uniquely positioned to scale. I’m particularly excited to contribute my operational experience to help Visby streamline manufacturing and drive down unit costs — essential steps in making the technology accessible to millions and building a strong foundation for long-term growth.”
Chuck Alpuche
